Squarepoint’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Squarepoint’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-159	Closed	-$6K	–	3580
2022 Q2	$6K	Sell	159 -9	-5%	-$281	﹤0.01%	2803
2022 Q1	$7K	Sell	168 -27	-14%	-$1.16K	﹤0.01%	2732
2021 Q4	$8K	Buy	195 +6	+3%	+$374	﹤0.01%	3104
2021 Q3	$13K	Sell	189 -1,442	-88%	-$106K	﹤0.01%	2831
2021 Q2	$126K	Buy	1,631 +1,447	+786%	+$88.1K	﹤0.01%	2974
2021 Q1	$12K	Buy	+184	New	+$14.3K	﹤0.01%	3037
2020 Q4	–	Sell	-315	Closed	-$17K	–	3353
2020 Q3	$17K	Buy	315 +86	+38%	+$5.1K	﹤0.01%	2423
2020 Q2	$9K	Buy	+229	New	+$7.83K	﹤0.01%	2167
2018 Q4	–	Sell	-144	Closed	-$35K	–	2311
2018 Q3	$35K	Buy	+144	New	+$34.1K	﹤0.01%	1929

Other funds holding DMK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Squarepoint's DMK Position: Q3 2022 in Review

Squarepoint sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q3 2022, closing a stake of 159 shares — an estimated $6K sold.

Squarepoint first reported a position in DMK in Q3 2018 and held it in 9 quarters. The position peaked at $126K in Q2 2021. 43 funds tracked by Wall St. Rank hold DMK as of Q3 2022.

Squarepoint reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q3 2022 after selling out during the quarter.
Squarepoint sold 159 DMK Pharmaceuticals Corporation Common Stock shares in Q3 2022, an estimated $6K.
Squarepoint first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q3 2018 and held it in 9 quarters.
Squarepoint's DMK Pharmaceuticals Corporation Common Stock position peaked at $126K in Q2 2021.
43 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q3 2022.

Based on Squarepoint's 13F filing for Q3 2022, filed 14 Nov 2022.